查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1949353

全球大分子药物原料药CDMO市场规模、份额、趋势和成长分析报告（2026-2034年）

Global Large Molecule Drug Substance CDMO Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 136 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计大分子原料药的CDMO市场将从2025年的228.8亿美元成长到2034年的533.7亿美元，2026年至2034年的复合年增长率为9.87%。

由于生物製药日益复杂以及对创新治疗方法的需求不断增长，大分子原料药的合约研发生产机构（CDMO）市场预计将显着扩张。随着製药公司将重点转向生物製药，对专业化生产能力的需求变得至关重要。该市场的特点是从传统的小分子药物转向大分子疗法，包括单株抗体、重组蛋白和基因疗法。这些产品的复杂性要求采用先进的生产流程、严格的品管和合规性——而这正是CDMO具有独特优势的领域。

此外，个人化医疗的兴起正在推动对生物製药疗法的需求，进一步加速大分子药物原料药CDMO市场的成长。随着医疗系统日益采用精准医疗方法，大规模生产客製化生物製药的能力将成为製药公司的关键差异化优势。投资于一次性系统和连续生产等先进技术的CDMO可望获得竞争优势。此外，生物製药公司与CDMO之间的策略联盟将促进创新，加速新型治疗方法的研发，确保市场保持活力并能回应不断变化的医疗保健需求。

全球大分子原料原料药生产力机构（CDMO）的发展趋势也受到不断变化的监管环境和永续性的永续发展意识的影响。随着监管机构简化生物製药的核准流程，新治疗方法的上市时间缩短，为CDMO创造了更灵活的营运环境。此外，将永续实践融入生产流程不仅满足监管要求，也符合消费者对环境友善医疗保健解决方案日益增长的需求。随着市场的发展，那些优先考虑创新、合作和永续性的CDMO将在这个快速成长的产业中占据有利地位，并取得成功。

目录

第一章 引言

第二章执行摘要

第三章 市场变数、趋势与框架

  • 市场谱系展望
  • 绘製渗透率和成长前景图
  • 价值链分析
  • 法律规范
    • 标准与合规性
    • 监管影响分析
  • 市场动态
    • 市场驱动因素
    • 市场限制
    • 市场机会
    • 市场问题
  • 波特五力分析
  • PESTLE分析

4. 全球大分子药物原料药CDMO市场（依服务类型划分）

  • 市场分析、洞察与预测
  • 契约製造
  • 合约开发

5. 全球大分子药物原料药CDMO市场（依来源划分）

  • 市场分析、洞察与预测
  • 哺乳动物
  • 微生物来源
  • 其他的

6. 全球大分子药物原料药CDMO市场（依最终用户划分）

  • 市场分析、洞察与预测
  • 生技公司
  • CRO
  • 其他的

7. 全球大分子药物原料药CDMO市场（依地区划分）

  • 区域分析
  • 北美市场分析、洞察与预测
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲市场分析、洞察与预测
    • 英国
    • 法国
    • 德国
    • 义大利
    • 俄罗斯
    • 其他欧洲国家
  • 亚太市场分析、洞察与预测
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 东南亚
    • 其他亚太国家
  • 拉丁美洲市场分析、洞察与预测
    • 巴西
    • 阿根廷
    • 秘鲁
    • 智利
    • 其他拉丁美洲国家
  • 中东和非洲市场分析、洞察与预测
    • 沙乌地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中东和非洲国家

第八章 竞争情势

  • 最新趋势
  • 公司分类
  • 供应链和销售管道合作伙伴（根据现有资讯）
  • 市场占有率和市场定位分析（基于现有资讯）
  • 供应商格局（基于现有资讯）
  • 策略规划

第九章：公司简介

  • 主要公司的市占率分析
  • 公司简介
    • Eurofins Scientific
    • WuXi Biologics
    • Samsung Biologics
    • Catalent Inc
    • Rentschler Biopharma SE
    • AGC Biologics
    • Recipharm AB
    • Siegfried Holding AG
    • Boehringer Ingelheim
    • FUJIFILM Diosynth Biotechnologies
简介目录
Product Code: VMR112110346

The Large Molecule Drug Substance CDMO Market size is expected to reach USD 53.37 Billion in 2034 from USD 22.88 Billion (2025) growing at a CAGR of 9.87% during 2026-2034.

The Large Molecule Drug Substance Contract Development and Manufacturing Organization (CDMO) market is poised for significant expansion, driven by the increasing complexity of biologics and the growing demand for innovative therapies. As pharmaceutical companies pivot towards biologics, the need for specialized manufacturing capabilities becomes paramount. This market is characterized by a shift from traditional small-molecule drugs to large-molecule therapeutics, including monoclonal antibodies, recombinant proteins, and gene therapies. The intricate nature of these products necessitates advanced manufacturing processes, stringent quality control, and regulatory compliance, which CDMOs are uniquely positioned to provide.

Moreover, the rise of personalized medicine is catalyzing the demand for tailored biologic therapies, further propelling the growth of the Large Molecule Drug Substance CDMO market. As healthcare systems increasingly adopt precision medicine approaches, the ability to produce customized biologics at scale will be a critical differentiator for pharmaceutical companies. CDMOs that invest in cutting-edge technologies, such as single-use systems and continuous manufacturing, will likely gain a competitive edge. Additionally, strategic partnerships between biopharmaceutical companies and CDMOs will enhance innovation and expedite the development of novel therapies, ensuring that the market remains dynamic and responsive to emerging healthcare needs.

The global landscape for Large Molecule Drug Substance CDMOs is also influenced by regulatory advancements and the increasing focus on sustainability. As regulatory bodies streamline approval processes for biologics, the time-to-market for new therapies will decrease, fostering a more agile environment for CDMOs. Furthermore, the integration of sustainable practices in manufacturing processes will not only meet regulatory requirements but also align with the growing consumer demand for environmentally responsible healthcare solutions. As the market evolves, CDMOs that prioritize innovation, collaboration, and sustainability will be well-positioned to thrive in this burgeoning sector.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Service

  • Contract Manufacturing
  • Contract Development

By Source

  • Mammalian
  • Microbial
  • Others

By End-User

  • Biotech Companies
  • CRO
  • Other

COMPANIES PROFILED

  • Eurofins Scientific, WuXi Biologics, Samsung Biologics, Catalent Inc, Rentschler Biopharma SE, AGC Biologics, Recipharm AB, Siegfried Holding AG, Boehringer Ingelheim, FUJIFILM Diosynth Biotechnologies

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL LARGE MOLECULE DRUG SUBSTANCE CDMO MARKET: BY SERVICE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Service
  • 4.2. Contract Manufacturing Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Contract Development Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL LARGE MOLECULE DRUG SUBSTANCE CDMO MARKET: BY SOURCE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Source
  • 5.2. Mammalian Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Microbial Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL LARGE MOLECULE DRUG SUBSTANCE CDMO MARKET: BY END-USER 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast End-user
  • 6.2. Biotech Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. CRO Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL LARGE MOLECULE DRUG SUBSTANCE CDMO MARKET: BY REGION 2022-2034(USD MN)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.2.1 By Service
    • 7.2.2 By Source
    • 7.2.3 By End-user
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.3.1 By Service
    • 7.3.2 By Source
    • 7.3.3 By End-user
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Russia
    • 7.3.9 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.4.1 By Service
    • 7.4.2 By Source
    • 7.4.3 By End-user
    • 7.4.4 India
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 Australia
    • 7.4.8 South East Asia
    • 7.4.9 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.5.1 By Service
    • 7.5.2 By Source
    • 7.5.3 By End-user
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 South East Asia
    • 7.5.9 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.6.1 By Service
    • 7.6.2 By Source
    • 7.6.3 By End-user
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL LARGE MOLECULE DRUG SUBSTANCE CDMO INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 Eurofins Scientific
    • 9.2.2 WuXi Biologics
    • 9.2.3 Samsung Biologics
    • 9.2.4 Catalent Inc
    • 9.2.5 Rentschler Biopharma SE
    • 9.2.6 AGC Biologics
    • 9.2.7 Recipharm AB
    • 9.2.8 Siegfried Holding AG
    • 9.2.9 Boehringer Ingelheim
    • 9.2.10 FUJIFILM Diosynth Biotechnologies